AP 24534

Biological Activity for AP 24534

Technical Data for AP 24534

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for AP 24534

References for AP 24534

References are publications that support the biological activity of the product.

• Gozgit et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol.Cancer Ther., 2011;10:1028 PMID: 21482694
• O'Hare et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009;16:401 PMID: 19878872
• Gordon et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Nature, 2020; PMID: 32353859
• Huang et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) J.Med.Chem., 2010;53:4701 PMID: 20513156